{
    "organizations": [],
    "uuid": "31c0d6dd9d7003146185a18f068b1dec4f09681f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-tax-reform-relatively-neutral-for/brief-tax-reform-relatively-neutral-for-mylan-cfo-idUSL1N1P422G",
    "ord_in_thread": 0,
    "title": "BRIEF-Tax reform relatively neutral for Mylan-CFO",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 56 PM / Updated 5 minutes ago BRIEF-Tax reform relatively neutral for Mylan-CFO Reuters Staff \nJan 9 (Reuters) - Mylan: \n* SAYS ITS BIOSIMILAR FOR AMGEN‘S NEULASTA COULD BE A “MID-YEAR OPPORTUNITY” \n* SAYS U.S. TAX REFORM RELATIVELY NEUTRAL FOR THE COMPANY Source text for Eikon: Further company coverage: (Reporting By Michael Erman)",
    "published": "2018-01-10T01:55:00.000+02:00",
    "crawled": "2018-01-10T02:07:15.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "reform",
        "relatively",
        "neutral",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "mylan",
        "say",
        "biosimilar",
        "amgen",
        "neulasta",
        "could",
        "opportunity",
        "say",
        "tax",
        "reform",
        "relatively",
        "neutral",
        "company",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "michael",
        "erman"
    ]
}